Description
Join us for an interactive workshop on evaluating disease-causing DNA variants for their eligibility for antisense oligonucleotide (ASO) therapies. Gain hands-on experience with the newly developed N1C VARIANT guidelines, an international consensus framework for assessing a variant’s ASO-amenability. Through live variant assessments, participants will learn how to apply these guidelines in clinical and research settings, equipping them with the knowledge and tools to implement their own ASO-amenability screening programs.
